Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline

Teva Pharmaceutical Industries CEO Richard Francis detailed the company's strategic shift towards biopharmaceuticals, aiming to stabilize its generics business while growing its innovative medicines portfolio. The company's innovative sales have reached approximately $1 billion per quarter, with marketed growth products showing double-digit gains. Teva targets a 30% operating margin by 2027, driven by a cost-efficiency program expected to yield $700 million in savings. This margin expansion will be balanced with continued investment in its pipeline, which includes regular product launches supported by brands like AUSTEDO and AJOVY, and pipeline candidates such as duvakitug and ecopipam. The company also boasts a biosimilars portfolio of 15 marketed products and 14 in development. Francis noted that Teva's gross margin has improved to about 55% and expects further gains as innovative products contribute more to sales. The company is on track to meet its 2027 operating margin target, despite anticipated losses from generic REVLIMID sales. Teva plans to allocate capital strategically to projects with expected returns, avoiding fixed R&D budgets or 'pet projects'. The pipeline features innovative medicines like duvakitug (for inflammatory conditions), anti-IL-15 programs, long-acting olanzapine, ecopipam (for Tourette syndrome), and UZEDY. Teva anticipates launching a new product annually for the next five years, followed by launches approximately every 18 months.